Publicacions<\/h2>\n\t\t\t\t![\"103-viroterapiadelcancer-ralemany-def\"](\"https:\/\/idibell.cat\/wp-content\/uploads\/2020\/04\/103-viroterapiadelcancer-ralemany-def.jpeg\" "\\"103-viroterapiadelcancer-ralemany-def\\"")
\n\t\t\t\t\tL\u00ednies estrat\u00e8giques<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tCerca de dianes tumorals dels adenovirus oncol\u00edtics (Ramon Alemany)
\nDifusi\u00f3 intratumoral d’adenovirus oncol\u00edtics a trav\u00e9s de barreres estromals (Ramon Alemany)
\nImmunoter\u00e0pia indu\u00efda per l’onc\u00f2lica (Ramon Alemany \/ Rafa Moreno)
\nImmunoter\u00e0pia basada en neoepitopis del c\u00e0ncer (Ramon Alemany \/ Rafa Moreno \/ Josep Maria Piulats \/ V\u00edctor Moreno)
\nC\u00e8l\u00b7lules mare mesenquimals com a portadores d’adenovirus oncol\u00edtics (Rafa Moreno)
\nAn\u00e0lisi de laboratori associat a assajos cl\u00ednics amb adenovirus oncol\u00edtics (Rafa Moreno i Marcel Costa)\n\t\t\t\t\tPublicacions seleccionades<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPowles,T;Yuen,KC;Gillessen,S;Kadel EE,3RD; Rathkopf,D; Matsubara,N; Drake,CG et al, Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial<\/strong>., Nat. Med., 2022;28(1):144-153, doi:10.1038\/s41591-021-01600-6,<\/p>\nCarvajal,RD;Butler,MO;Shoushtari,AN;Hassel,JC;Ikeguchi,A;Hernandez Aya,L;Nathan,P et al, Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial<\/strong>., Nat. Med., 2022;doi:10.1038\/s41591-022-02015-7,<\/p>\nMar\u00edn Jim\u00e9nez,JA;Garc\u00eda Mulero,S;Mat\u00edas Guiu,X;Piulats,JM, Facts and hopes in immunotherapy of endometrial cancer<\/strong>., Clin. Cancer Res., 2022;28(22):4849-4860, doi:10.1158\/1078-0432.CCR-21-1564<\/p>\nGarcia Carbonero,R;Bazan Peregrino,M;Gil Martin,M; Alvarez,R;Macarulla,T; Riesco Martinez,MC;Verdaguer,H et al, Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors<\/strong>, J. Immunother. Cancer, 2022;10(3):doi:10.1136\/jitc-2021-003255<\/p>\nGuix,I;Liu,Q;Pujana,MA;Ha,P;Piulats,J;Linares,I;Guedea,F et al, Validation of anti-correlated TGF\u00df signaling and alternative end-joining DNA repair signatures that predict response to genotoxic cancer therapy<\/strong>., Clin. Cancer Res., 2022;28(7):1372-1382, doi:10.1158\/1078-0432.CCR-21-2846<\/p>\n\t\t\t\t\tProjectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t20FIS039. Phase II stUdy of ALoCelyvir in patientS with mEtastatic Uveal Melanoma (PULSE-UM)<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 694346,29. 2020-2023. PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\nMCI21009. Inducci\u00f3n de muerte celular inmunog\u00e9nica en tumores mediante el uso de adenovirus oncol\u00edticos armados<\/strong>. Ministry of Science and Innovation (MICINN) Budget: 266200. 2021-2024. PI: Alemany Bonastre, Ram\u00f3n.<\/p>\nFIS21131. RICORS TERAV<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 170999,99. 2022-2024. PI: Alemany Bonastre, Ram\u00f3n.<\/p>\n19ACL065. ESTUDIO DE FASE 2, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR EL TRATAMIENTO CON ACETATO DE ABIRATERONA M\u00c1S PREDNISONA CON O SIN ABEMACICLIB EN PACIENTES CON C\u00c1NCER DE PR\u00d3STATA RESISTENTE A LA CASTRACI\u00d3N METAST\u00c1SICO<\/strong>. Lilly S.A. Budget: 308260. 2019- . PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n19ACL080. Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab (MK-3475) m\u00e1s docetaxel m\u00e1s prednisona frente a un placebo m\u00e1s docetaxel m\u00e1s prednisona en participantes con c\u00e1ncer de pr\u00f3stata resistente a la castraci\u00f3n metast\u00e1sico (CPRCm) sin quimioterapia previa que han mostrado progresi\u00f3n con un f\u00e1rmaco hormonal de \u00faltima generaci\u00f3n (FHUG) (KEYNOTE-921)<\/strong>. MERCK SHARP & DOHME ESPA\u00d1A S.A. Budget: 262983. 2019- . PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n\t\t\t\t\tTransfer\u00e8ncia<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT005-ADENOVIRUS ONCOL\u00cdTICOS PARA EL TRATAMIENTO DEL C\u00c1NCER
\nIP: Ramon Alemany
\nES200901201\nPAT040-ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY
\nIP: Ramon Alemany
\nEP14382162\nLicense: Adenovirus comprising an albumin-binding molety
\nPI: Dr. Ramon Alemany
\nLicense: Adenovirus onol\u00edticos para el tratamiento del c\u00e1ncer
\nPI: Dr. Manel Cascall\u00f3\n\t\t\t\t\tM\u00e9s informaci\u00f3<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tActualment, els virus desenvolupats pel grup estan sent provats en assajos cl\u00ednics liderats per empreses biotecnol\u00f2giques. Entre aquestes, VCN Biosciences \u00e9s una spin-off del grup. El grup tamb\u00e9 analitza par\u00e0metres virals i immunol\u00f2gics en mostres de pacients.<\/p>\n\t\t\t\t![\"Alemany](\"https:\/\/idibell.cat\/wp-content\/uploads\/2019\/10\/alemany-bonastre-ramon-150x150.jpg\" "\\"alemany-bonastre-ramon\\"")
\n
\n\t\tAlemany Bonastre, Ramon\n\t<\/h4>\n\n\t\t\n\t\tralemany@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t![\"Josep-Maria-Piulats-Rodriguez\"](\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/10\/Josep-Maria-Piulats-Rodriguez-150x150.jpg\" "\\"Josep-Maria-Piulats-Rodriguez\\"")
\n\n\t\tPiulats, Rodriguez, Josep Maria\n\t<\/h4>\n\n\t\t\n\t\tjpiulats@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t\n\n\t\tAlemany Bonastre, Ramon\n\t<\/h4>\n\n\t\t\n\t\tralemany@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n\n\t\tPiulats, Rodriguez, Josep Maria\n\t<\/h4>\n\n\t\t\n\t\tjpiulats@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t![\"Rafael-Moreno-Olie\"](\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/04\/Rafael-Moreno-Olie-150x150.png\" "\\"Rafael-Moreno-Olie\\"")
\n\n\t\tMoreno Oli\u00e9, Rafael\n\t<\/h4>\n\n\t\t\n\t\trmoreno@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n\n\t\t\n\t\tProCURE\n\t\t<\/a>\n\t<\/h4>\n\n\t\t\n\t\tSpanish Adenovirus Network\n\t\t<\/a>\n\t<\/h4>\n\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tCaps de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es postdoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es predoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\tCaps de grup\n\t\t\t\t\t\t\t\t\t\t\t\n- Alemany Bonastre, Ram\u00f3n<\/li>\n
- Piulats, Rodriguez, Josep Maria<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es principals\n\t\t\t\t\t\t\t\t\t\t\t
\n- Moreno Oli\u00e9, Rafael<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\n\t\t\t\t\t\t\t\t\t\t\t
\n- Buisan Rueda, Oscar<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es postdoctorals\n\t\t\t\t\t\t\t\t\t\t\t
\n- Costa Garcia, Marcel<\/li>\n
- Espinosa Carrasco, Gabriel<\/li>\n
- Franco Luzon, Lidia<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es predoctorals\n\t\t\t\t\t\t\t\t\t\t\t
\n- Moya Borrego, Laura<\/li>\n
- Del Carpio Hureta, Luis Paul<\/li>\n
- Carne Martin, Sebastian Ciro<\/li>\n
- Mar\u00edn Jim\u00e9nez, Juan Antonio<\/li>\n
- Fiol Mata, Pau<\/li>\n<\/ul>\n\t\t\t\t\t\tSuport cient\u00edfic\n\t\t\t\t\t\t\t\t\t\t\t
\n- Torres Manjon, Silvia<\/li>\n
- Codony Servat, Carles<\/li>\n<\/ul>\n
\n\t\tNot\u00edcies relacionades\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tPresenten un virus oncol\u00edtic dirigit a c\u00e8l\u00b7lules NK amb gran potencial antitumoral<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t12\/01\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tC\u00e8l\u00b7lules mare modificades gen\u00e8ticament per impulsar la immunoter\u00e0pia contra el c\u00e0ncer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t25\/05\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn f\u00e0rmac que impedeix la reparaci\u00f3 de l’ADN podria millorar la superviv\u00e8ncia dels pacients amb un dels c\u00e0ncers de pr\u00f2stata m\u00e9s agressius<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t23\/02\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tTanquem un 2021 ple de ci\u00e8ncia!<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t30\/12\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tL’IDIBELL rep m\u00e9s d’un mili\u00f3 i mig d’euros de l’AECC per finan\u00e7ar projectes d’investigaci\u00f3 contra el c\u00e0ncer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/11\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn nou f\u00e0rmac incrementa l’esperan\u00e7a de vida dels pacients amb un c\u00e0ncer intraocular molt agressiu<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t27\/09\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tDos investigadors de l’IDIBELL reben el suport de la Fundaci\u00f3 Mutua Madrile\u00f1a<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/06\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL celebra el Kickoff Meeting sobre els Projectes d’Investigaci\u00f3 en Salut concedits per l’ISCIII<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t20\/04\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL celebra el Kickoff Meeting dels projectes finan\u00e7ats per La Fundaci\u00f3 La Marat\u00f3 de TV3 2019<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t18\/11\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tTroben caracter\u00edstiques immunes comunes en les met\u00e0stasis de pulm\u00f3 a les que dirigir futurs tractaments<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/07\/2020\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"Immunoter\u00e0pia del C\u00e0ncer Resum El Grup de Viroter\u00e0pia del C\u00e0ncer explora nous tractaments contra el c\u00e0ncer basats en adenovirus oncol\u00edtics i altres immunoter\u00e0pies. El grup pret\u00e9n dissenyar i avaluar adenovirus oncol\u00edtics com a agents antitumors contra diferents tumors s\u00f2lids. Les principals l\u00ednies de recerca s\u00f3n la cerca de dianes tumorals, la difusi\u00f3 intratumoral a trav\u00e9s […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-10 06:15:32","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2391"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=2391"}],"version-history":[{"count":7,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2391\/revisions"}],"predecessor-version":[{"id":25397,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2391\/revisions\/25397"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=2391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Carvajal,RD;Butler,MO;Shoushtari,AN;Hassel,JC;Ikeguchi,A;Hernandez Aya,L;Nathan,P et al, Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial<\/strong>., Nat. Med., 2022;doi:10.1038\/s41591-022-02015-7,<\/p>\n Mar\u00edn Jim\u00e9nez,JA;Garc\u00eda Mulero,S;Mat\u00edas Guiu,X;Piulats,JM, Facts and hopes in immunotherapy of endometrial cancer<\/strong>., Clin. Cancer Res., 2022;28(22):4849-4860, doi:10.1158\/1078-0432.CCR-21-1564<\/p>\n Garcia Carbonero,R;Bazan Peregrino,M;Gil Martin,M; Alvarez,R;Macarulla,T; Riesco Martinez,MC;Verdaguer,H et al, Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors<\/strong>, J. Immunother. Cancer, 2022;10(3):doi:10.1136\/jitc-2021-003255<\/p>\n Guix,I;Liu,Q;Pujana,MA;Ha,P;Piulats,J;Linares,I;Guedea,F et al, Validation of anti-correlated TGF\u00df signaling and alternative end-joining DNA repair signatures that predict response to genotoxic cancer therapy<\/strong>., Clin. Cancer Res., 2022;28(7):1372-1382, doi:10.1158\/1078-0432.CCR-21-2846<\/p>\n\t\t\t\t\tProjectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t 20FIS039. Phase II stUdy of ALoCelyvir in patientS with mEtastatic Uveal Melanoma (PULSE-UM)<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 694346,29. 2020-2023. PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n MCI21009. Inducci\u00f3n de muerte celular inmunog\u00e9nica en tumores mediante el uso de adenovirus oncol\u00edticos armados<\/strong>. Ministry of Science and Innovation (MICINN) Budget: 266200. 2021-2024. PI: Alemany Bonastre, Ram\u00f3n.<\/p>\n FIS21131. RICORS TERAV<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 170999,99. 2022-2024. PI: Alemany Bonastre, Ram\u00f3n.<\/p>\n 19ACL065. ESTUDIO DE FASE 2, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR EL TRATAMIENTO CON ACETATO DE ABIRATERONA M\u00c1S PREDNISONA CON O SIN ABEMACICLIB EN PACIENTES CON C\u00c1NCER DE PR\u00d3STATA RESISTENTE A LA CASTRACI\u00d3N METAST\u00c1SICO<\/strong>. Lilly S.A. Budget: 308260. 2019- . PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n 19ACL080. Estudio de fase 3, aleatorizado y doble ciego de pembrolizumab (MK-3475) m\u00e1s docetaxel m\u00e1s prednisona frente a un placebo m\u00e1s docetaxel m\u00e1s prednisona en participantes con c\u00e1ncer de pr\u00f3stata resistente a la castraci\u00f3n metast\u00e1sico (CPRCm) sin quimioterapia previa que han mostrado progresi\u00f3n con un f\u00e1rmaco hormonal de \u00faltima generaci\u00f3n (FHUG) (KEYNOTE-921)<\/strong>. MERCK SHARP & DOHME ESPA\u00d1A S.A. Budget: 262983. 2019- . PI: Piulats Rodr\u00edguez, Josep Mar\u00eda.<\/p>\n\t\t\t\t\tTransfer\u00e8ncia<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT005-ADENOVIRUS ONCOL\u00cdTICOS PARA EL TRATAMIENTO DEL C\u00c1NCER Actualment, els virus desenvolupats pel grup estan sent provats en assajos cl\u00ednics liderats per empreses biotecnol\u00f2giques. Entre aquestes, VCN Biosciences \u00e9s una spin-off del grup. El grup tamb\u00e9 analitza par\u00e0metres virals i immunol\u00f2gics en mostres de pacients.<\/p>\n\t\t\t\t Immunoter\u00e0pia del C\u00e0ncer Resum El Grup de Viroter\u00e0pia del C\u00e0ncer explora nous tractaments contra el c\u00e0ncer basats en adenovirus oncol\u00edtics i altres immunoter\u00e0pies. El grup pret\u00e9n dissenyar i avaluar adenovirus oncol\u00edtics com a agents antitumors contra diferents tumors s\u00f2lids. Les principals l\u00ednies de recerca s\u00f3n la cerca de dianes tumorals, la difusi\u00f3 intratumoral a trav\u00e9s […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-10 06:15:32","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2391"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=2391"}],"version-history":[{"count":7,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2391\/revisions"}],"predecessor-version":[{"id":25397,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2391\/revisions\/25397"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=2391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nIP: Ramon Alemany
\nES200901201\nPAT040-ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY
\nIP: Ramon Alemany
\nEP14382162\nLicense: Adenovirus comprising an albumin-binding molety
\nPI: Dr. Ramon Alemany
\nLicense: Adenovirus onol\u00edticos para el tratamiento del c\u00e1ncer
\nPI: Dr. Manel Cascall\u00f3\n\t\t\t\t\tM\u00e9s informaci\u00f3<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t\n\n\t\tAlemany Bonastre, Ramon\n\t<\/h4>\n
\n\t\t\n\t\tralemany@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t
\n\n\t\tPiulats, Rodriguez, Josep Maria\n\t<\/h4>\n
\n\t\t\n\t\tjpiulats@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t
\n\n\t\tAlemany Bonastre, Ramon\n\t<\/h4>\n
\n\t\t\n\t\tralemany@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t
\n\n\t\tPiulats, Rodriguez, Josep Maria\n\t<\/h4>\n
\n\t\t\n\t\tjpiulats@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t
\n\n\t\tMoreno Oli\u00e9, Rafael\n\t<\/h4>\n
\n\t\t\n\t\trmoreno@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n
\n\t\t\n\t\tProCURE\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\tSpanish Adenovirus Network\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tCaps de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es postdoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es predoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\tCaps de grup\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n
\n
\n
\n
\n\t\tNot\u00edcies relacionades\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tPresenten un virus oncol\u00edtic dirigit a c\u00e8l\u00b7lules NK amb gran potencial antitumoral<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t12\/01\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tC\u00e8l\u00b7lules mare modificades gen\u00e8ticament per impulsar la immunoter\u00e0pia contra el c\u00e0ncer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t25\/05\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn f\u00e0rmac que impedeix la reparaci\u00f3 de l’ADN podria millorar la superviv\u00e8ncia dels pacients amb un dels c\u00e0ncers de pr\u00f2stata m\u00e9s agressius<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t23\/02\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tTanquem un 2021 ple de ci\u00e8ncia!<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t30\/12\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tL’IDIBELL rep m\u00e9s d’un mili\u00f3 i mig d’euros de l’AECC per finan\u00e7ar projectes d’investigaci\u00f3 contra el c\u00e0ncer<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/11\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn nou f\u00e0rmac incrementa l’esperan\u00e7a de vida dels pacients amb un c\u00e0ncer intraocular molt agressiu<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t27\/09\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tDos investigadors de l’IDIBELL reben el suport de la Fundaci\u00f3 Mutua Madrile\u00f1a<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/06\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL celebra el Kickoff Meeting sobre els Projectes d’Investigaci\u00f3 en Salut concedits per l’ISCIII<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t20\/04\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tIDIBELL celebra el Kickoff Meeting dels projectes finan\u00e7ats per La Fundaci\u00f3 La Marat\u00f3 de TV3 2019<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t18\/11\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tTroben caracter\u00edstiques immunes comunes en les met\u00e0stasis de pulm\u00f3 a les que dirigir futurs tractaments<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/07\/2020\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"